Health & Biotech
At Paradigm, we firmly believe that the key to addressing unmet medical needs lies in unlocking the potential of forgotten compounds. Our strategy is to take unconventional routes to develop safe and effective treatments for clinical conditions that lack viable options.
Our current primary focus is the development of injectable pentosan polysulfate sodium (iPPS/Zilosul®), for the treatment of osteoarthritis (OA). An ability to provide a safe an effective treatment for OA is a blockbuster market opportunity as there are limited therapeutic solutions available. We’ve charged ahead into global phase 3 trials, addressing the core components of the disease: inflammation, pain, and regeneration. Zilosul® possesses the remarkable potential to provide long-term pain reduction and modify the underlying course of this debilitating disease.
With our headquarters in Melbourne, Australia, and strategic offices in the European Union and the United States, Paradigm is poised to make a global impact. Our international presence reflects our commitment to delivering ground breaking treatments to patients worldwide.
KEY PEOPLE
RELATED STOCKHEAD STORIES
News
10 at 10: These ASX stocks are flying into orbit this morning
Health & Biotech
ASX Health Stocks: Resapp gains on India COVID-19 trial, Atomo to supply HIV self-test in Australia
Health & Biotech
ASX Health Wrap: Resonance gains ground, with sights set on FDA approval for LiverSmart
News
Market Highlights and 5 ASX Small Caps to watch on Wednesday
Health & Biotech
Check Up: Paradigm targets Phase 3 clinical trial in the US; AI microbiology product fails to impress
Health & Biotech
ASX Health Stocks: Invex jumps 14pc after deal in Korea, Noxopharm gets US Patent nod
News
10 at 10: These ASX stocks have something to crow about this morning
News
Market Highlights and 5 ASX Small Caps to watch on Friday
Health & Biotech
ASX health stocks: Mayne Pharma slapped with lawsuit, Patrys encounters clinical trial delays
News
Last Orders: Tech leads the ASX 200 to finish just over the line
News
ASX Small Cap Lunch Wrap: Who’s about to confess their sins?
News
Last Orders: What you might have missed on the ASX today
Experts
Scopo’s powerplays: Hemp hippies and wellness wonderlands
News
Top 50 ASX small caps of 2018: Where are they now?
Health & Biotech
We’re still here: investors keen on health despite market shun
Health & Biotech
Dr Boreham’s Crucible: Why Invex has all the right ingredients to possibly become a takeover target
Director Trades